AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
The Drug Discovery World Podcast
DDW Highlights: 22 January 2024
Jan 22, 2024
Exploring antibodies targeting spike protein epitopes to neutralize armicron variants, advancements in TB vaccine delivery, immune responses to SARS-CoV-2 variants, vaccine responses across age groups, and genetic modification in stem cell transplantation research.
14:03
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Exavir Bio's XV-R012 targets conserved epitopes to combat COVID-19 variants effectively.
- Jenner Institute research explores inhalation delivery of BCG vaccine for enhanced immune responses against TB.
Deep dives
Exavir Bio's New Antibodies Against COVID-19 Armicron Variants
Exavir Bio has introduced XV-R012, a combination of XV-R013M and XV-R014 antibodies that target crucial epitopes in the SARS-CoV spike protein. These antibodies have shown significant potency in neutralizing various coronaviruses and current circulating variants. Exavir Bio's CEO, Dr. Torsten Momin-Rauer, expressed the continuous threat of COVID-19, especially for vulnerable populations like the elderly and immunocompromised individuals. The unique approach of targeting conserved epitopes with XV-R012 is expected to combat a wide range of COVID-19 variants, emphasizing the need for ongoing innovative solutions.
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode